NCT04754425 2026-02-06
Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Dana-Farber Cancer Institute
University Health Network, Toronto